Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (5332)	9/18/1998 3:47:00 PM
From: Joe E.	Read Replies (3) \| Respond to of 6136

It looks to me like today's move in both Vertex and Agouron may be the result of the high percentage of people experiencing side effects with Sustiva as mentioned in Dupont's press release: "Safety data from clinical trials show Sustiva is generally well tolerated. The most significant adverse events associated with Sustiva therapy are nervous system symptoms, which are reported in approximately half of patients (e.g., dizziness, insomnia, somnolence, impaired concentration and abnormal dreaming). The discontinuation rate for nervous system symptoms was 2.6 percent. These symptoms occur early in treatment and generally resolve within a few weeks. Rarely, patients have more serious side effects that may affect mood or ability to think clearly. Mild to moderate skin rash was reported in approximately one out of four patients. The incidence of severe rash was less than 1 percent. The discontinuation rate for rash in clinical trials was 1.7 percent. Women should not become pregnant while taking Sustiva because birth defects have been seen in animals given Sustiva." Perhaps Sustiva will not be as competitive as first thought. The Dupont release is at: dupont.com